ERBB2 and breast cancer: Primary tumors included lung cancer in 67 (51.1%; NSCLC: 51, SCLC: 14, NET/lung neuroendocrine tumor: 2), breast cancer in 26 (19.8%; ER-/PR-/HER2-: 5, ER+/PR+/HER2-: 7, HER2+: 7, N/A: 7), melanoma in 7 (5.3%), colo-rectal carcinoma in 7 (5.3%), and renal cell carcinoma in 4 (3.1%) patients.